Skip to main content

VIFOR PHARMA Value Stock - Dividend - Research Selection

Vifor Pharma AG

ISIN: CH0364749348, WKN: A2DRZ4

Market price date: 18.01.2022
Market price: 161,90 CHF


Vifor Pharma AG Fundamental data and company key figures of the share

Annual reports in CHF
Key figures 26-09-2021
Cash flow
Net operating cash flow 423.800.000
Capital Expenditures -68.500.000
Free cash flow 355.300.000
Balance sheet
Total Equity 3.569.800.000
Liabilities & Shareholders equity 5.211.700.000
Income statement
Net income 359.600.000
Eps (diluted) 5,545
Diluted shares outstanding 64.855.200
Net sales/revenue 1.705.600.000

Fundamental ratios calculated on: 18-01-2022

Ratios
Key figures 18-01-2022
Cash flow
P/C 24,78
   
P/FC 29,55
Balance sheet
ROI6,90
ROE68,50
Income statement
P/E29,20
Div. Yield1,24%
P/B2,94
P/S6,16


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolVIFN.SW
Market Capitalization10.756.050.944,00 USD
CountrySwitzerland
IndicesSTOXX EUROPE 600,MSCI World Index
SectorsPharmaceuticals
Raw Data SourceIFRS in Millionen CHF
Stock Split2017-05-22,10.000000/1.000000; 2003-02-25,2.000000/1.000000
Internetwww.viforpharma.com


Description of the company

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.viforpharma.com


NEWS